Director
Novartis
Fort Worth, Texas, United States
Matt Fidler, M.Stat. Ph.D. works as a Director in Pharmacometrics and is the lead in the nlmixr2 ecosystem. He has over 15 years of drug development experience and currently is working in Ophthalmology and Immunology disease areas. He is passionate about open source and nonlinear mixed effects methodology. He started work on the nlmixr2/rxode2 (then nlmixr and RxODE) 2017 and the ecosystem has evolved to allow interchange of common model formats with the new babelmixr2. He is also the education chair for the SxP SIG
Disclosure information not submitted.
Advancing Automation Tools to Accelerate Drug Development: Cross-SIG Perspectives
Tuesday, October 21, 2025
1:45 PM - 3:15 PM MDT
Panel - Advancing Automation Tools to Accelerate Drug Development: Cross-SIG Perspectives
Tuesday, October 21, 2025
2:45 PM - 3:15 PM MDT